Summary
The purpose of this study is to evaluate whether enhanced dermatologic management can
reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of
interest (DAEIs) when compared with standard-of-care skin management in participants with
locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor
(EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and
lazertinib. A substudy will enroll participants from Arms A and B who experience specific
new-onset or persistent DAEIs (Grade >=2) during treatment with intravenous (IV)
amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic
treatment strategies in these participants.